92 research outputs found
State-resolved measurements of single-electron capture in slow Ne7+- and Ne8+-helium collisions
Single-electron capture in collisions of 9 keV x q Ne8+ and Ne7+ ions with He has been studied using cold-target recoil-ion momentum spectroscopy. With an improved apparatus a longitudinal momentum resolution of 0.07 au has been achieved. This momentum component is directly proportional to the difference in the binding energy of the active electron between the final and the initial state. For the first time state- resolved differential cross sections have been determined with respect to the main quantum number, subshell level and spin state of the captured electron. A comparison with recent theoretical results for energy levels in Be-like Ne is given
Multiply charged ions from solid substances with the mVINIS Ion Source
We have used the well known metal-ions-from-volatile-compounds (MIVOC) method at the mVINIS Ion Source to produce the multiply charged ion beams form solid substances. Based on this method the very intense and stable multiply charged ion beams of several solid substances having the high melting points were extracted. The ion yields and the spectra of multiply charged ion beams obtained from solid materials like Fe and Hf will be presented. We have utilized the multiply charged ion beams from solid substances to irradiate the polymers, fullerenes and glassy carbon at the low energy channel for modification of materials.13th International Conference on Physics of Highly Charged Ions, Aug 28-Sep 01, 2006, Queens Univ, Belfast, Irelan
EUV spectra of highly-charged ions W-W relevant to ITER diagnostics
We report the first measurements and detailed analysis of extreme ultraviolet
(EUV) spectra (4 nm to 20 nm) of highly-charged tungsten ions W to
W obtained with an electron beam ion trap (EBIT). Collisional-radiative
modelling is used to identify strong electric-dipole and magnetic-dipole
transitions in all ionization stages. These lines can be used for impurity
transport studies and temperature diagnostics in fusion reactors, such as ITER.
Identifications of prominent lines from several W ions were confirmed by
measurement of isoelectronic EUV spectra of Hf, Ta, and Au. We also discuss the
importance of charge exchange recombination for correct description of
ionization balance in the EBIT plasma.Comment: 11 pages, 4 figure
Progress at the Heidelberg EBIT
Two years after the relocation of the Heidelberg EBIT, several experiments are already in operation. Spectroscopic measurements in the optical region have delivered the most precise reported wavelengths for highly charged ions, in the case of the forbidden transitions of Ar XIV and Ar XV. The lifetimes of the metastable levels involved in those transitions has been determined with an error of less than 0.2%. A new, fully automatized x-ray crystal spectrometer allows systematic measurements with very high precision and reproducibility. Absolute measurements of the Lyman series of H-like ions are currently underway. Dielectronic recombination studies have yielded information on rare processes, as two-electron-one photon transitions in Ar16+, or the interference effects between dielectronic and radiative recombination in Hg77+. The apparatus can now operate at electron beam currents of more than 500 mA, and energies up to 100 keV. A further beam energy increase is planned in the near future. Ions can be extracted from the trap and transported to external experiments. Up to 4 x 107 Ar16+ ions per second can be delivered to a 1 cm diameter target at 10 m distance. Charge-exchange experiments with U64+ colliding with a cold He atomic beam have been carried out, as well as experiments aiming at the optimization of the charge state distribution of the extracted via dielectronic recombination. Two new EBITs, currently in advanced state of construction in Heidelberg, will be used for experiments at the VUV free electron laser at TESLA (Hamburg) and for the charge breeding of short-lived radioactive isotopes at the TRIUMF ISAC facility
Comparative Analysis of Legislative Requirements About Patients' Access to Biotechnological Drugs for Rare Diseases in Central and Eastern European Countries
Objectives: The aim of the study was to compare the access of patients with rare diseases (RDs) to biotechnological drugs in several Central and Eastern European countries (CEECs). We focused on the legislative pricing and reimbursement requirements, availability of biotechnological orphan medicinal products (BOMPs) for RDs, and reimbursement expenditures. Methods: A questionnaire-based survey was conducted among experts from 10 CEECs: Bulgaria, Croatia, Estonia, Greece, Hungary, Poland, Romania, Slovakia, Serbia, and Macedonia. The legal requirements for reimbursement and pricing of BOMPs were collected. All BOMPs and medicines without prior orphan designations were extracted from the European list of orphan medicinal products, 2017. The reimbursement status of these medicinal products in 2017 in the public coverage of the included CEECs as well as the share of their costs in relation to the total public pharmaceutical spending for the period from 2014 to 2016 were defined. Results: Our survey revealed that some differences in the legal requirements for pricing and reimbursement of BOMPs amongst the countries included in the study. All European Union countries have developed and implemented pharmacoeconomic guidelines with or without some specific reimbursement requirements for orphan medicinal products. Cost-effectiveness analysis, cost-utility analysis, Markov models, meta-analysis, and discount levels of costs and results were required only in Bulgaria, Poland and Hungary. The number of reimbursed BOMPs and biotechnological medicinal products for RDs without prior orphan designation was the highest in Hungary (17 and 40, respectively). Patient-based reimbursement schemes were available only in Hungary for 11 out of 17 BOMPs. Poland and Greece have the highest pharmaceutical expenditure of reimbursed BOMPs with are similar to 214 million and 180 million EUR, respectively in the observed period from 2014 to 2016. High proportion of the pharmaceutical expenditure on the reimbursed biotechnological medicinal products for RDs for the observed period 2014-2016 is presented in Bulgaria and Slovakia. Conclusions: The non-European Union CEECs face a significant delay in the legal implementation of pharmacoeconomic guideline for assessment of BOMPs. The access to BOMPs is similar among the observed CEECs and the countries with the best access are Hungary and Greece. The influence of BOMP expenditures on the budget in the individual countries is significant
Effects of hospital facilities on patient outcomes after cancer surgery: an international, prospective, observational study
Background Early death after cancer surgery is higher in low-income and middle-income countries (LMICs) compared with in high-income countries, yet the impact of facility characteristics on early postoperative outcomes is unknown. The aim of this study was to examine the association between hospital infrastructure, resource availability, and processes on early outcomes after cancer surgery worldwide.Methods A multimethods analysis was performed as part of the GlobalSurg 3 study-a multicentre, international, prospective cohort study of patients who had surgery for breast, colorectal, or gastric cancer. The primary outcomes were 30-day mortality and 30-day major complication rates. Potentially beneficial hospital facilities were identified by variable selection to select those associated with 30-day mortality. Adjusted outcomes were determined using generalised estimating equations to account for patient characteristics and country-income group, with population stratification by hospital.Findings Between April 1, 2018, and April 23, 2019, facility-level data were collected for 9685 patients across 238 hospitals in 66 countries (91 hospitals in 20 high-income countries; 57 hospitals in 19 upper-middle-income countries; and 90 hospitals in 27 low-income to lower-middle-income countries). The availability of five hospital facilities was inversely associated with mortality: ultrasound, CT scanner, critical care unit, opioid analgesia, and oncologist. After adjustment for case-mix and country income group, hospitals with three or fewer of these facilities (62 hospitals, 1294 patients) had higher mortality compared with those with four or five (adjusted odds ratio [OR] 3.85 [95% CI 2.58-5.75]; p<0.0001), with excess mortality predominantly explained by a limited capacity to rescue following the development of major complications (63.0% vs 82.7%; OR 0.35 [0.23-0.53]; p<0.0001). Across LMICs, improvements in hospital facilities would prevent one to three deaths for every 100 patients undergoing surgery for cancer.Interpretation Hospitals with higher levels of infrastructure and resources have better outcomes after cancer surgery, independent of country income. Without urgent strengthening of hospital infrastructure and resources, the reductions in cancer-associated mortality associated with improved access will not be realised
- …